70.69
price up icon2.60%   1.79
 
loading
Schlusskurs vom Vortag:
$68.90
Offen:
$70.465
24-Stunden-Volumen:
798.03K
Relative Volume:
0.44
Marktkapitalisierung:
$13.68B
Einnahmen:
$4.41B
Nettoeinkommen (Verlust:
$21.27M
KGV:
220.91
EPS:
0.32
Netto-Cashflow:
$288.81M
1W Leistung:
+2.11%
1M Leistung:
+5.10%
6M Leistung:
-2.54%
1J Leistung:
+7.43%
1-Tages-Spanne:
Value
$70.41
$70.78
1-Wochen-Bereich:
Value
$67.17
$70.78
52-Wochen-Spanne:
Value
$53.56
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
Firmenname
Incyte Corp
Name
Telefon
(302) 498-6700
Name
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Mitarbeiter
2,617
Name
Twitter
@Incyte
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
INCY's Discussions on Twitter

Vergleichen Sie INCY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INCY
Incyte Corp
70.69 13.34B 4.41B 21.27M 288.81M 0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-16 Hochstufung Stifel Hold → Buy
2025-03-18 Herabstufung Guggenheim Buy → Neutral
2025-03-18 Herabstufung William Blair Outperform → Mkt Perform
2024-12-17 Eingeleitet UBS Neutral
2024-10-29 Hochstufung BofA Securities Neutral → Buy
2024-10-01 Eingeleitet Wolfe Research Outperform
2024-09-18 Herabstufung Truist Buy → Hold
2024-07-02 Herabstufung BMO Capital Markets Market Perform → Underperform
2024-05-23 Eingeleitet Deutsche Bank Hold
2024-04-23 Eingeleitet Cantor Fitzgerald Neutral
2024-02-23 Eingeleitet Jefferies Buy
2024-02-14 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 Hochstufung Leerink Partners Market Perform → Outperform
2023-12-04 Hochstufung Guggenheim Neutral → Buy
2023-11-21 Herabstufung Goldman Buy → Neutral
2023-07-25 Eingeleitet Citigroup Buy
2023-05-04 Herabstufung BofA Securities Buy → Neutral
2023-04-10 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-03-24 Hochstufung SVB Securities Underperform → Market Perform
2023-01-31 Eingeleitet Piper Sandler Overweight
2022-08-03 Herabstufung Evercore ISI Outperform → In-line
2022-08-03 Herabstufung Guggenheim Buy → Neutral
2022-07-28 Eingeleitet Wells Fargo Equal Weight
2022-02-09 Herabstufung SVB Leerink Mkt Perform → Underperform
2022-01-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-19 Eingeleitet BMO Capital Markets Market Perform
2021-07-20 Hochstufung The Benchmark Company Hold → Buy
2021-02-10 Herabstufung SVB Leerink Mkt Perform → Underperform
2021-01-07 Eingeleitet Truist Buy
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-06-16 Eingeleitet The Benchmark Company Hold
2020-05-06 Herabstufung JP Morgan Overweight → Neutral
2020-04-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-04-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-24 Fortgesetzt William Blair Outperform
2020-03-13 Hochstufung BofA/Merrill Neutral → Buy
2020-02-04 Fortgesetzt BofA/Merrill Neutral
2020-01-03 Bestätigt BMO Capital Markets Market Perform
2020-01-03 Herabstufung Mizuho Buy → Neutral
2020-01-02 Herabstufung Guggenheim Buy → Neutral
2019-10-03 Eingeleitet Mizuho Buy
2019-09-12 Eingeleitet BMO Capital Markets Market Perform
2019-09-05 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 Fortgesetzt Morgan Stanley Equal-Weight
2019-09-05 Hochstufung Oppenheimer Perform → Outperform
2019-05-21 Eingeleitet Credit Suisse Neutral
2019-05-03 Herabstufung Barclays Overweight → Equal Weight
2019-04-11 Eingeleitet Stifel Hold
2019-04-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-01-24 Hochstufung William Blair Mkt Perform → Outperform
Alle ansehen

Incyte Corp Aktie (INCY) Neueste Nachrichten

pulisher
Jul 23, 2025

What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

What drives Incyte Corporation stock priceRapid capital growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 17, 2025

Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 16, 2025

Incyte EVP Flannelly sells $83k in shares - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK

Jul 16, 2025
pulisher
Jul 16, 2025

Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo

Jul 15, 2025
pulisher
Jul 15, 2025

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Incyte stock price target raised to $62 from $61 at UBS on sales outlook - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Sun Pharma Shares Climb 3%, Leqselvi Settlement - Rediff

Jul 15, 2025
pulisher
Jul 14, 2025

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S. - The Hindu

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp - Business Standard

Jul 14, 2025
pulisher
Jul 14, 2025

India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settled - The Economic Times

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma Settles Incyte Corp Litigation - Rediff

Jul 14, 2025
pulisher
Jul 14, 2025

India's Sun Pharma launches anti-baldness drug Leqselvi in US - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Sun Pharma settles litigation with Incyte Corp - Press Trust of India

Jul 14, 2025
pulisher
Jul 10, 2025

Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance

Jul 10, 2025
pulisher
Jul 10, 2025

Incyte’s Q2 2025 Earnings: What To Expect - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

Incyte to Report Second Quarter Financial Results - Business Wire

Jul 10, 2025
pulisher
Jul 09, 2025

William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey

Jul 09, 2025
pulisher
Jul 06, 2025

Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo

Jul 06, 2025
pulisher
Jul 03, 2025

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha

Jul 03, 2025
pulisher
Jul 02, 2025

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 02, 2025
pulisher
Jun 30, 2025

Meury named Incyte CEO as Hoppenot departs - Delaware Business Times

Jun 30, 2025
pulisher
Jun 30, 2025

Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran” - Insider Monkey

Jun 30, 2025
pulisher
Jun 27, 2025

Incyte Corporation (INCY) Announces Leadership Transition with N - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Bill Meury Takes Helm at Incyte (INCY) as New CEO | INCY Stock N - GuruFocus

Jun 27, 2025
pulisher
Jun 26, 2025

Incyte Appoints Bill Meury Chief Executive Officer - Contract Pharma

Jun 26, 2025
pulisher
Jun 26, 2025

Citi reiterates buy rating on Incyte stock amid CEO transition - Investing.com

Jun 26, 2025
pulisher
Jun 24, 2025

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN

Jun 24, 2025
pulisher
Jun 24, 2025

How Is Incyte’s Stock Performance Compared To Other Biotech Stocks? - Barchart.com

Jun 24, 2025
pulisher
Jun 23, 2025

Incyte stock falls after FDA extends review of pediatric eczema cream - Investing.com

Jun 23, 2025
pulisher
Jun 22, 2025

5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call - Yahoo Finance

Jun 22, 2025
pulisher
Jun 20, 2025

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis - Business Wire

Jun 20, 2025
pulisher
Jun 19, 2025

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Jun 16, 2025
pulisher
Jun 16, 2025

Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Alopecia Areata Market Expected to Experience Major Growth - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance

Jun 16, 2025

Finanzdaten der Incyte Corp-Aktie (INCY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):